Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as well as the factors affecting loss to follow-up after anti-VEGF therapy.
The poster ‘Loss to Follow-Up in Patients With nAMD Treated With Anti-VEGF Therapy in the U.S.’ was presented at the annual American Academy of Ophthalmology (AAO) meeting, 30 September – 3 October 2022
- What is the impact of loss to follow up after anti-vascular endothelial growth factor (anti-VEGF) injections among patients with neovascular age-related macular degeneration (nAMD)? (00:19)
- What were the objectives and design of your study? (00:46)
- What were the overall findings of the study? (01:11)
- What factors affected loss to follow up? (02:19)
- What interventions may improve outcomes? (02:50)
Disclosure: Rahul Khurana has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of AAO 2022.
